Study of an Interposition Supraciliary Implant in Patients With Open Angle Glaucoma

Ciliatech19 enrolled

Overview

The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.

19 patients with primary open angle glaucoma (POAG) refractory to topical medical therapy were operated in late 2020 and a novel interposition supraciliary device implanted. These patients reached 6 months follow-up and the original study had to be interrupted. This observational study prolonges follow-up to 36 months

Study Type

OBSERVATIONAL

Enrollment

Conditions

Glaucoma, Open-Angle

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients who were implanted in this center with the novel supraciliary interposition device under the scope of clinical trial NCT03736655 Exclusion Criteria: * if cannot assist to all future follow-up visits

Locations (1)

Malayan Center

Yerevan, Armenia

Outcomes

Primary Outcomes

Assess post-op IOP reduction

Proportion of Eyes With Intraocular Pressure (IOP) Reduction of ≥ 20%

Time frame: 12, 24 and 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.